Read the media coverage in the Handelszeitung about CUTISS broadening our Management Team.
Month: October 2019
Zurich, Switzerland, October 28 2019 – CUTISS AG, an innovative Swiss life-science Company aiming to provide patients that suffer from large and deep skin defects with an automatically produced, personalized skin tissue therapy, denovoSkin™, today announced it has further enhanced its Management Team.
As per October 1, Kathi Mujynya Ludunge has been appointed Chief Operation Officer of CUTISS. She will be responsible for the Company’s operations as well as for all Manufacturing/ GMP/Quality activities (clinical and commercial products). Kathi joins CUTISS from the Skin Research Institute of Singapore /A*STAR (Agency for Sciences, Technology and Research), where she was working since 2016 as Head of Operations of the Asian Skin Bank Platform. Prior to her relocation to Singapore, Kathi held several leading positions in life-sciences, among those managing GMP manufacturing and development projects for Healthpoint Therapeutics (Switzerland and USA), as well as leading the Manufacturing, Sciences and Technology (MSAT) department at Smith & Nephew (Fort Worth, Texas).
Kathi started her professional career in Switzerland as a scientist at the Institute of Pathology of the University of Berne, followed by the position as Production Manager at the Lausanne-based LifeScience-Start Up Modex Therapeutics/Isotis, before joining DFB Pharmaceuticals (Lausanne). Kathi is a Cell Biologist by training (Neuchatel School of Health), then gained project management expertise with her MBA (University of Geneva), followed by a post-grade diploma in Management of Biotech and Pharmaceuticals venture at EPFL (Lausanne). She holds a dual citizenship (Switzerland and USA).
Kathi Mujynya Ludunge said: “I am not only happy to return to Switzerland with my husband and move our family back home to Switzerland, but also to join CUTISS, an emerging and life-science start up with a clear vision”. Dr. Daniela Marino, Chief Executive Officer and Co-Founder of CUTISS AG, commented: “We are excited that Kathi has decided to return to Switzerland after many years abroad to support us in achieving our goals. With her know-how now, the expertise in skin bioengineering of CUTISS’ management team sums up to 100 years”.
About CUTISS AG
CUTISS is a Swiss Life science Company, spin-off of the University of Zurich, developing personalized skin graft technologies for the treatment of a large spectrum of skin defects. Its lead product candidate, denovoSkin™, has been tested in a phase I clinical trial on pediatric patients at the University Children’s Hospital in Zurich. Phase II studies are currently ongoing in Switzerland and the European Union and are funded by Wyss Zurich. denovoSkin™ has received Orphan Drug Designation for the treatment of burns by Swissmedic, EMA and FDA. In addition, denovoSkin™ promises to improve life quality of elective (reconstructive) patients as well and it can further be developed in terms of complexity by adding pigmentation.
CUTISS AG, CEO Daniela Marino, +41 76 230 8046, firstname.lastname@example.org, www.cutiss.swiss
Read about CUTISS growing skin in the latest edition of FORBES no. 9 / 2019
(This article is only available in German.)
“Ein briefmarkengroßes Stück Haut
innerhalb eines Monats um das
Siebzigfache vergrößern – bei Cutiss
ist das Realität. Das Life-Science Unternehmen aus Zürich arbeitet an
einer innovativen Art der Hauttransplantation, der Denovoskin-Technologie…”
Read about CUTISS in the Swiss Health Insurer Sanitas’ Magazine:
Our body is covered with around 1.7 square metres of skin. If this protection is missing, for example due to extensive burns, reserve skin is needed for skin grafts within a short period of time. Zurich-based start-up Cutiss has developed a new process to bio-engineer the required skin…